NCT04929249: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04929249 |
|---|---|
| Title | A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (≥70 mg/dL) Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 25, 2021 |
| Completion date | Sept. 15, 2023 |
| Required reporting date | Sept. 14, 2024, midnight |
| Actual reporting date | Aug. 20, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |